Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on October 16, 2020, covering events occurring on October 13, 2020. The filing details the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Structure: The Company sold 7,180,000 "Firm Shares" and granted an option for 1,077,000 "Option Shares," which was exercised in full by the underwriters.
- Total Shares Sold: 8,257,000 shares of Common Stock.
- Public Offering Price: $9.75 per share.
- Price to Company: $9.165 per share (after underwriting discounts).
- Net Proceeds: Approximately $75.2 million after underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: Jefferies LLC and Piper Sandler & Co. acted as representatives.
Material Changes
The primary material change reported is the execution of the Underwriting Agreement on October 13, 2020, and the subsequent full exercise of the underwriters' option to purchase additional shares. This transaction significantly increases the Company's cash position through the issuance of new equity. The filing does not provide comparative financial metrics (e.g., revenue or profit) for prior periods as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
The closing of the offering was expected to take place on October 16, 2020, subject to customary closing conditions. The shares were issued pursuant to an effective shelf registration statement on Form S-3. The filing incorporates press releases from October 13 and October 14, 2020, by reference, which typically contain management's intended use of proceeds and strategic outlook, though specific commentary text is not included in the body of this 8-K. Standard risks associated with equity offerings, such as dilution to existing shareholders, are inherent in the transaction.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $75.2 million net proceeds receipt.
- Review the attached press releases (Exhibits 99.1 and 99.2) for the specific intended use of proceeds.
- Check the Company's subsequent filings for the updated share count and diluted earnings per share impact.
- Confirm the status of the underwriters' option exercise in the final closing documents.